BRISTOL-MYERS SQUIBB COMPANY vs ELI LILLY AND COMPANY, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BMY and LLY diverge most: on ev/ebitda, BMY reads 46.4 and LLY reads 2152.1; on revenue growth, BMY reads +3.1% and LLY reads +49.9%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BMY | LLY |
|---|---|---|
| Price | $63.62 | $1114.83 |
| Market cap | $130.3B | $1.05T |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +21.4% |
| P/E | 14.0 | 37.4 |
| P/B | 5.84 | 30.98 |
| P/S | 2.65 | 13.17 |
| EV/EBITDA | 46.4 | 2152.1 |
| Revenue growth | +3.1% | +49.9% |
| Net margin | 18.9% | 33.5% |
| Return on equity | 41.6% | 78.8% |
| Return on assets | 10.6% | 18.8% |
| FCF yield | 8.8% | 2.7% |
| Dividend yield | 3.9% | 0.6% |
| Debt / equity | 1.97 | 1.62 |
| Current ratio | 1.53 | 1.35 |
| Altman Z (solvency) | 2.22 | 7.02 |
| Piotroski F (quality) | 8 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.